Sanofi Genzyme Launches Innovative and Educational Audio Adventure Series for People Treated with ALPROLIX®

Cambridge, MA--(BUSINESS WIRE)--Sanofi Genzyme, the specialty care business unit of Sanofi, today announced the launch of a first-of-its-kind audio adventure series designed to provide an engaging and educational infusion experience for ALPROLIX® Coagulation Factor IX (Recombinant), Fc Fusion Protein patients and their caregivers. Sanofi Genzyme will debut Infusion Squad at The Coalition for Hemophilia B’s Annual Symposium in Orlando, Florida, from March 14 -17 in booth #19.

Part educational and part entertaining, each three- to five-minute audio adventure takes hemophilia B patients on an exciting infusion mission in the bloodstream with a team of “Infusionauts”. Along the way, listeners learn about prepping for an infusion, the importance of prophylactic treatment, safety considerations, and the role of factor IX in hemophilia B.

Kim Phelan, Vice President of The Coalition for Hemophilia B commented, “We are very excited about Sanofi Genzyme’s new audio adventure series. We believe providing engaging and educational tools like this new skill for Alexa have the potential to improve the infusion experience for families experiencing hemophilia B.”

The series currently consists of eight different stories created based on recent patient research and focus groups that revealed parents and caregivers often find it challenging for young patients to sit still during the 15- to 20-minute infusion process. Additionally, they expressed a need for educational materials to help families learn about hemophilia B and infusing. The Infusion Squad skill for Amazon Alexa is available on Alexa-enabled devices.

“We are committed to meaningfully improving the lives of patients and their caregivers,” said Jeff Schaffnit, Head of U.S. Rare Blood Disorders at Sanofi Genzyme. “Our goal with this adventure series is to keep patients involved during their treatment while also providing a creative and fun way to learn how ALPROLIX works in the body, with a little help from some heroic characters who share their mission.”

Patients and caregivers can enable the skill on the Alexa app, Alexa Skills Store, or on any Alexa-enabled device by saying “Alexa, open Infusion Squad”.

About Hemophilia B

Hemophilia B is caused by having substantially reduced or no factor IX activity, which is needed for normal blood clotting.i The World Federation of Hemophilia estimates that approximately 29,700 people are currently diagnosed with hemophilia B worldwide.ii People with hemophilia B may experience bleeding episodes in joints and muscles that cause pain, decreased mobility and irreversible joint damage. In the worst cases, these bleeding episodes can cause organ bleeds and life-threatening hemorrhages. Infusions of factor IX temporarily replace clotting factors necessary to resolve bleeding and, when used prophylactically, to prevent new bleeding episodes.i

Indications and Important Safety Information

Indications

ALPROLIX is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.Important Safety Information

Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system. These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, and if bleeding is not controlled using ALPROLIX.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Your body can also make antibodies called “inhibitors” against ALPROLIX, which may stop ALPROLIX from working properly.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots.  Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Full Prescribing Information.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life


i World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: February 11, 2016.

ii World Federation of Hemophilia. Report on the Annual Global Survey 2016. Available at: http://www1.wfh.org/publications/files/pdf-1690.pdf. Accessed on: 12 March, 2019.

 

 

FIX-US-6168 v2 03/19

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.
OK